A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Conditions
- Diffuse Large B-Cell LymphomaDLBCL
- Interventions
- Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
- Registration Number
- NCT05139017
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxaliplatin (R-GemOx) is superior to R-GemOx with respect to progression-free survival (PFS) per Lugano response criteria by blinded independent review committee (BICR); and that ZV in combination with bendamustine rituximab (BR) is superior to BR with respect to PFS per Lugano response criteria by BICR.
With protocol amendment 4 (effective: 04-April-2024), enrollment in Cohort B (study arms Bendamustine Rituximab \[BR\] and ZV + BR) is discontinued. No efficacy outcome analysis and hypothesis testing will be conducted for Cohort B.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 290
- Has a histologically confirmed diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL).
- Has radiographically measurable DLBCL per the Lugano Response Criteria, as assessed locally by the investigator.
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 within 7 days prior to study treatment initiation.
- Has adequate organ function.
- Is able to provide new or archival tumor tissue sample not previously irradiated.
Zilovertamab vedotin plus R-GemOx, or R-GemOx study arms:
- Has relapsed or refractory DLBCL and is ineligible for or have failed autologous stem-cell transplant (ASCT) and have failed at least 1 line of prior therapy.
- Has post-chimeric antigen receptor T (post-CAR-T) cell therapy failure or is ineligible for CAR-T cell therapy.
Not applicable with protocol amendment 4: Zilovertamab vedotin plus Bendamustine Rituximab (BR), and Bendamustine Rituximab study arms:
- Has relapsed or refractory DLBCL and is ineligible for or have failed ASCT and have failed at least 2 lines of prior therapy.
- Has post-CAR-T therapy failure or is ineligible for CAR-T cell therapy.
- Not applicable with protocol amendment 4: Has history of transformation of indolent disease to DLBCL
- Has received solid organ transplant at any time.
- Has received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL).
- Has clinically significant (ie, active) cardiovascular disease or serious cardiac arrhythmia requiring medication.
- Has ongoing graft-versus-host disease (GVHD) of any grade, or is receiving treatment for their GVHD.
- Has clinically significant pericardial or pleural effusion.
- Has ongoing Grade >1 peripheral neuropathy.
- Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years.
- Has a demyelinating form of Charcot-Marie-Tooth disease.
- Has contraindication to any of the study intervention components including but not limited to prior anaphylactic reaction.
- Has received prior systemic anticancer therapy, including investigational agents within 4 weeks prior to the first dose of study intervention.
- Has received prior radiotherapy within 4 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
- Has ongoing corticosteroid therapy.
- Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention.
- Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention.
- Has known active central nervous system (CNS) lymphoma involvement or active CNS involvement by lymphoma. Participants with prior CNS involvement are eligible if their CNS disease is in radiographic, cytological (for cerebrospinal fluid disease), and clinical remission.
- Has an active infection requiring systemic therapy.
- Has a known history of human immunodeficiency virus (HIV) infection.
- Has a known active Hepatitis C virus infection.
- Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description ZV + R-GemOx (Part 1) Zilovertamab vedotin Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Gemcitabine 1000 mg/m\^2 and Oxaliplatin 100 mg/m\^2 (R-GemOx) given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles. ZV + R-GemOx (Part 1) Rituximab Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Gemcitabine 1000 mg/m\^2 and Oxaliplatin 100 mg/m\^2 (R-GemOx) given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles. ZV + R-GemOx (Part 1) Gemcitabine Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Gemcitabine 1000 mg/m\^2 and Oxaliplatin 100 mg/m\^2 (R-GemOx) given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles. ZV + R-GemOx (Part 1) Oxaliplatin Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Gemcitabine 1000 mg/m\^2 and Oxaliplatin 100 mg/m\^2 (R-GemOx) given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles. ZV + R-GemOx (Part 1) Granulocyte Colony-Stimulating Factor (G-CSF) Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Gemcitabine 1000 mg/m\^2 and Oxaliplatin 100 mg/m\^2 (R-GemOx) given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles. ZV + R-GemOx (Part 2) Zilovertamab vedotin Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + R-GemOx (Part 2) Rituximab Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + R-GemOx (Part 2) Gemcitabine Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + R-GemOx (Part 2) Oxaliplatin Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + R-GemOx (Part 2) Granulocyte Colony-Stimulating Factor (G-CSF) Using the recommended Phase 2 dose (RP2D) dose of ZV plus R-GemOx from Part 1, participants will receive ZV plus R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. R-GemOx (active control for Part 2) Rituximab Participants will receive R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. R-GemOx (active control for Part 2) Gemcitabine Participants will receive R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. R-GemOx (active control for Part 2) Oxaliplatin Participants will receive R-GemOx given intravenously on Day 1 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + BR (Part 2) Zilovertamab vedotin Using RP2D from Part 1, participants will receive ZV plus Rituximab 375 mg/m\^2, given intravenously on Day 1 and Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2, of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + BR (Part 2) Rituximab Using RP2D from Part 1, participants will receive ZV plus Rituximab 375 mg/m\^2, given intravenously on Day 1 and Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2, of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + BR (Part 2) Bendamustine Using RP2D from Part 1, participants will receive ZV plus Rituximab 375 mg/m\^2, given intravenously on Day 1 and Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2, of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + BR (Part 2) Granulocyte Colony-Stimulating Factor (G-CSF) Using RP2D from Part 1, participants will receive ZV plus Rituximab 375 mg/m\^2, given intravenously on Day 1 and Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2, of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. Bendamustine Rituximab (BR) Rituximab Participants will receive Rituximab 375 mg/m\^2, given intravenously on Day 1 Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. Bendamustine Rituximab (BR) Bendamustine Participants will receive Rituximab 375 mg/m\^2, given intravenously on Day 1 Bendamustine 90 mg/m\^2 given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles or until progressive disease or discontinuation. ZV + BR (Part 1) Zilovertamab vedotin Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Bendamustine 90 mg/m\^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles. ZV + BR (Part 1) Rituximab Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Bendamustine 90 mg/m\^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles. ZV + BR (Part 1) Bendamustine Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Bendamustine 90 mg/m\^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles. ZV + BR (Part 1) Granulocyte Colony-Stimulating Factor (G-CSF) Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Bendamustine 90 mg/m\^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles.
- Primary Outcome Measures
Name Time Method Number of participants who experienced an adverse event (AE) Up to ~68 months An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experienced an AE will be reported.
Number of participants who discontinued study treatment due to an AE Up to ~68months An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinued study treatment due to an AE will be reported.
Overall survival (OS) Up to ~35 months OS, defined as the time from randomization to death due to any cause will be reported.
Progression-free survival (PFS) Up to ~26 months PFS, defined as the time from randomization to the first documented disease progression per Lugano response criteria as assessed by BICR or death due to any cause, whichever occurs first will be presented.
Number of participants who experienced dose-limiting toxicities (DLTs) in Part 1 Up to ~6 weeks The CTCAE, Version 5.0 will be used to grade the severity of AEs in this study. DLTs will be reported for Part 1 of this study.
- Secondary Outcome Measures
Name Time Method Objective response rate (ORR) Up to ~26 months ORR, defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) per Lugano criteria as assessed by BICR will be presented.
Duration of response (DOR) Up to ~26 months DOR, defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, will be reported.
Trial Locations
- Locations (95)
Carmel Hospital ( Site 1103)
🇮🇱Haifa, Israel
Bass Medical Group ( Site 0166)
🇺🇸Walnut Creek, California, United States
Innovative Clinical Research Institute ( Site 0122)
🇺🇸Whittier, California, United States
Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163)
🇺🇸Boca Raton, Florida, United States
Saint Elizabeth Medical Center Edgewood ( Site 0165)
🇺🇸Edgewood, Kentucky, United States
University of Kentucky Chandler Medical Center ( Site 0158)
🇺🇸Lexington, Kentucky, United States
Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133)
🇺🇸Louisville, Kentucky, United States
Louisiana State University Health Sciences Center New Orleans ( Site 0134)
🇺🇸New Orleans, Louisiana, United States
University of Maryland ( Site 0123)
🇺🇸Baltimore, Maryland, United States
Dana-Farber Cancer Institute-Lymphoma ( Site 0111)
🇺🇸Boston, Massachusetts, United States
University of Massachusetts Medical School ( Site 0119)
🇺🇸Worcester, Massachusetts, United States
St. Vincent Frontier Cancer Center-Research ( Site 0108)
🇺🇸Billings, Montana, United States
Atlantic Health System ( Site 0116)
🇺🇸Morristown, New Jersey, United States
Hadassah Medical Center ( Site 1100)
🇮🇱Jerusalem, Israel
New York Medical College ( Site 0113)
🇺🇸Valhalla, New York, United States
Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156)
🇺🇸Nashville, Tennessee, United States
Hospital Aleman ( Site 2200)
🇦🇷Buenos Aites, Caba, Argentina
Instituto Alexander Fleming ( Site 2201)
🇦🇷Caba, Argentina
Hospital Privado Universitario de Córdoba ( Site 2202)
🇦🇷Cordoba, Argentina
Townsville University Hospital ( Site 1800)
🇦🇺Douglas, Queensland, Australia
Grampians Health ( Site 1802)
🇦🇺Ballarat, Victoria, Australia
Liga Norte Riograndense Contra o Câncer ( Site 2305)
🇧🇷Natal, Rio Grande Do Norte, Brazil
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200)
🇨🇦Toronto, Ontario, Canada
Biocenter ( Site 2401)
🇨🇱Concepcion., Biobio, Chile
IC La Serena Research ( Site 2405)
🇨🇱La Serena, Coquimbo, Chile
Oncocentro Valdivia ( Site 2407)
🇨🇱Valdivia., Los Rios, Chile
Clínica Inmunocel ( Site 2404)
🇨🇱Santiago, Region M. De Santiago, Chile
Clínica RedSalud Vitacura ( Site 2409)
🇨🇱Santiago, Region M. De Santiago, Chile
Bradfordhill ( Site 2403)
🇨🇱Santiago, Region M. De Santiago, Chile
Beijing Cancer hospital ( Site 3000)
🇨🇳Beijing, Beijing, China
Chongqing University Cancer Hospital-Medical Oncology ( Site 3025)
🇨🇳Chongqing, Chongqing, China
Chongqing University Three Gorges Hospital ( Site 3026)
🇨🇳Chongqing, Chongqing, China
Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001)
🇨🇳Guangzhou, Guangdong, China
Zhujiang Hospital ( Site 3002)
🇨🇳Guangzhou, Guangdong, China
The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029)
🇨🇳Luoyang, Henan, China
Henan Cancer Hospital-hematology department ( Site 3013)
🇨🇳Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017)
🇨🇳Wuhan, Hubei, China
The First Affiliated Hospital of Nanchang University ( Site 3004)
🇨🇳Nanchang, Jiangxi, China
Jiangxi Provincial Cancer Hospital ( Site 3005)
🇨🇳Nanchang, Jiangxi, China
The First Hospital of Jilin University-Hematology ( Site 3012)
🇨🇳Changchun, Jilin, China
Fudan University Shanghai Cancer Center ( Site 3009)
🇨🇳Shanghai, Shanghai, China
West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016)
🇨🇳Cheng Du, Sichuan, China
Sichuan Cancer hospital-Oncology ( Site 3021)
🇨🇳Chengdu, Sichuan, China
Zhejiang Cancer Hospital ( Site 3014)
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027)
🇨🇳Hangzhou, Zhejiang, China
Hospital Pablo Tobon Uribe ( Site 0804)
🇨🇴Medellin, Antioquia, Colombia
Instituto Médico de Alta Tecnologia S.A.S ( Site 0803)
🇨🇴Monteria, Cordoba, Colombia
FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801)
🇨🇴Bogota, Distrito Capital De Bogota, Colombia
Oncologos del Occidente ( Site 0800)
🇨🇴Pereira., Risaralda, Colombia
Fundacion Valle del Lili ( Site 0802)
🇨🇴Cali, Valle Del Cauca, Colombia
Hospital Metropolitano - Sede Lindora ( Site 2500)
🇨🇷Santa Ana, San Jose, Costa Rica
CIMCA ( Site 2501)
🇨🇷San Jose, Costa Rica
centre hospitalier lyon sud-Service Hématologie ( Site 0702)
🇫🇷Pierre-Bénite, Rhone, France
Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700)
🇫🇷Paris, France
University Hospital of Alexandroupolis ( Site 0903)
🇬🇷Alexandroupolis, Anatoliki Makedonia Kai Thraki, Greece
Evangelismos General Hospital of Athens ( Site 0900)
🇬🇷Athens, Attiki, Greece
Regional General Hospital of Athens "Laiko" ( Site 0901)
🇬🇷Athens, Attiki, Greece
MEDI-K ( Site 2602)
🇬🇹Guatemala, Guatemala
Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601)
🇬🇹Guatemala, Guatemala
CELAN,S.A ( Site 2603)
🇬🇹Guatemala, Guatemala
Queen Mary Hospital ( Site 3100)
🇭🇰Hong Kong, Hong Kong
Princess Margaret Hospital ( Site 3101)
🇭🇰Hong Kong, Hong Kong
Emek Medical Center-Hematology Unit ( Site 1102)
🇮🇱Afula, Israel
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203)
🇮🇹Rozzano, Milano, Italy
IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200)
🇮🇹Bologna, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202)
🇮🇹Napoli, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204)
🇮🇹Roma, Italy
Seoul National University Hospital-Oncology ( Site 0302)
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center ( Site 0300)
🇰🇷Seoul, Korea, Republic of
Aotearoa Clinical Trials ( Site 0501)
🇳🇿Auckland, New Zealand
Clínica San Felipe ( Site 2805)
🇵🇪Lima, Peru
Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301)
🇵🇱Wroclaw, Dolnoslaskie, Poland
Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304)
🇵🇱Lublin, Lubelskie, Poland
Pratia MCM Krakow ( Site 1303)
🇵🇱Krakow, Malopolskie, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300)
🇵🇱Warszawa, Mazowieckie, Poland
Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302)
🇵🇱Gdynia, Pomorskie, Poland
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309)
🇵🇱Słupsk, Pomorskie, Poland
Pratia Onkologia Katowice ( Site 1306)
🇵🇱Katowice, Slaskie, Poland
Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400)
🇹🇭Bangkok, Krung Thep Maha Nakhon, Thailand
Chulalongkorn University ( Site 0402)
🇹🇭Pathumwan, Krung Thep Maha Nakhon, Thailand
Maharaj Nakorn Chiang Mai Hospital ( Site 0401)
🇹🇭Chiang Mai, Thailand
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912)
🇹🇷Yenimahalle, Ankara, Turkey
Ege University Medicine of Faculty ( Site 1902)
🇹🇷Bornova, Izmir, Turkey
Ankara University Hospital Cebeci-hematology ( Site 1901)
🇹🇷Ankara, Turkey
Mega Medipol-Hematology ( Site 1909)
🇹🇷Istanbul, Turkey
Dokuz Eylül Üniversitesi-Hematology ( Site 1905)
🇹🇷Izmir, Turkey
Ondokuz Mayıs Universitesi ( Site 1907)
🇹🇷Samsun, Turkey
MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000)
🇺🇦Cherkasy, Cherkaska Oblast, Ukraine
Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004)
🇺🇦Ivano-Frankivsk, Ivano-Frankivska Oblast, Ukraine
Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002)
🇺🇦Lviv, Lvivska Oblast, Ukraine
State non-profit enterprise National Cancer Institute ( Site 2001)
🇺🇦Kyiv, Ukraine
National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005)
🇺🇦Kyiv, Ukraine
Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2003)
🇺🇦Kyiv, Ukraine
Aberdeen Royal Infirmary ( Site 2104)
🇬🇧Aberdeen, Aberdeen City, United Kingdom
University College London Hospital-Cancer Clinical Trials Unit ( Site 2100)
🇬🇧London-Camden, London, City Of, United Kingdom